Related references
Note: Only part of the references are listed.Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Peter J. Goadsby et al.
BRAIN (2019)
Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
NEUROTHERAPEUTICS (2018)
Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
Eloisa Rubio-Beltran et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
Dawn C. Buse et al.
HEADACHE (2017)
Lasmiditan for the treatment of migraine
Matilde Capi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Theo Vos et al.
LANCET (2017)
Patterns of Use and Health Expenses Associated With Triptans Among Adults With Migraines
Jun Wu et al.
CLINICAL JOURNAL OF PAIN (2015)
Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
Daniel Serrano et al.
HEADACHE (2015)
Outcome for headache and pain-free nonresponders to treatment of the first attack: A pooled post-hoc analysis of four randomized trials of eletriptan 40 mg
Steve H. Landy et al.
CEPHALALGIA (2014)
Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
Richard B. Lipton et al.
HEADACHE (2013)
mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system
Dipak V. Amrutkar et al.
PAIN (2012)
Quantifying the return of headache in triptan-treated migraineurs: An observational study
Fred Sheftell et al.
CEPHALALGIA (2010)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Fixed-Dose Sumatriptan and Naproxen in Poor Responders to Triptans With a Short Half-Life
Ninan T. Mathew et al.
HEADACHE (2009)
Statistics in medicine - Reporting of subgroup analyses in clinical trials
Rui Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Triptan nonresponder studies: Implications for clinical practice
DW Dodick
HEADACHE (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment
RM Gallagher et al.
HEADACHE (2003)
Share Paper
